Global Biologics CDMO Market Revenue and Share Analysis Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics cdmo market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Biologics CDMO Market In The Period 2029-2034?

The biologics CDMO market has experienced rapid expansion in recent years. It is projected to grow from $21.3 billion in 2024 to $24.15 billion in 2025, at a compound annual growth rate (CAGR) of 13.4%. The historical growth can be attributed to factors such as the rise in biologics development, enhanced cost efficiency and flexibility, a focus on core competencies, adherence to regulatory compliance and quality assurance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market is projected for significant expansion in the coming years. This market is anticipated to reach a valuation of $41.53 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.5%. Factors driving this growth during the forecast period include a rising need for biologic treatments, the advent of biosimilars and biobetters, increased capital into biomanufacturing infrastructure, a move towards externalizing intricate processes, an emphasis on robust supply chains and risk mitigation, streamlined regulations, and faster approval pathways. Key developments expected in this period encompass broadening service offerings to provide comprehensive solutions, the widespread use of single-use technologies, incorporating continuous manufacturing methods, and the rise of highly specialized CDMOs.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Strategic Drivers Are Accelerating The Biologics CDMO Market Expansion?

The rising need for cell and genetic therapy is anticipated to fuel the expansion of the biologic CDMO market moving forward. These therapies represent advanced medical strategies that use living cells or genetic material to address the fundamental causes of diseases at a cellular or genetic level, potentially offering treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The increasing demand for cell and gene therapy is attributed to their potential to provide innovative disease treatments by targeting underlying genetic or cellular issues. Biologic CDMOs provide specialized expertise in handling living cells, viral vectors, and genetic material, which enables the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating the transition from research to clinical application. For instance, in January 2023, The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, reported that the gene, cell, and RNA therapy pipeline experienced 7% growth in 2022, accumulating a total of 3,726 therapies in development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the escalating demand for cell and genetic therapy is a key factor propelling the growth of the biologic CDMO market.

What Is The Detailed Segment Distribution Of The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Global Trends Impacting The Development Of The Biologics CDMO Market?

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. This technology generates therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These lines are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps overcome immunotherapy research and development challenges concerning the need for more potent antibody therapeutics. The cell line is stable, scalable, and productive, providing a comprehensive solution for therapeutic development from discovery-stage research through commercial manufacturing.

Who Are The Major Stakeholders Operating In The Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company

Biodegradable Plastics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report

Soap And Other Detergents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report

Detergent Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795